Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in HFrEF Patients With Obesity
NCT07738276Phase 3Not yet recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jul 2026
- Primary completion
- Jun 2027
01
Overview
A Phase 3 trial of tirzepatide in heart failure with reduced ejection fraction (HFrEF), obesity, sponsored by Shahid Beheshti University of Medical Sciences. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
03
Conditions
heart failure with reduced ejection fraction (HFrEF)obesity
Beyond the preview
Go deeper on NCT07738276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738276.